Drug Type siRNA |
Synonyms |
Target |
Mechanism GSTP1 inhibitors(Glutathione S-transferase Pi inhibitors), RNA interference |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 1 | US | 18 Mar 2019 | |
KRAS mutant Non-small Cell Lung Cancer | Phase 1 | US | 18 Mar 2019 | |
Pancreatic Cancer | Phase 1 | US | 18 Mar 2019 | |
Pancreatic Cancer | Preclinical | US | 18 Mar 2019 | |
Colorectal Cancer | Discovery | US | 18 Mar 2019 | |
Non-Small Cell Lung Cancer | Discovery | US | 18 Mar 2019 |
Phase 1 | 38 | (ggdzzyexog) = teryyttoyi pwifogdnps (muttdvtlqy ) View more | Positive | 05 Apr 2024 | |||
Phase 1 | 21 | (obbjuxceaw) = No treatment-related grade 4-5 AEs, the most common NBF-006-related AEs were Grade 1 or 2 arthralgia, diarrhea, fatigue, and vomiting (11% each) ekrdjmasbb (ctqvbnebce ) View more | Positive | 31 May 2023 | |||
(advanced non-small cell lung (NSCLC)) |